Molecular subtypes in cancers of the gastrointestinal tract

Nature Reviews Gastroenterology and Hepatology

Volumn 14, Issue 6, 2017, Pages 333-342

  Bijlsma, Maarten F ^a   Sadanandam, Anguraj ^b   Tan, Patrick ^c   Vermeulen, Louis ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME;

CANCER CLASSIFICATION; CANCER RECURRENCE; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL PRACTICE; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGUS CANCER; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; CLASSIFICATION; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION PROFILING; GENETICS; IMMUNOPHENOTYPING; MOLECULARLY TARGETED THERAPY; MUTATION; NEUROENDOCRINE TUMORS; NOMENCLATURE; PHENOTYPE; PROCEDURES; TUMOR GENE;

GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION PROFILING; GENES, NEOPLASM; HUMANS; IMMUNOPHENOTYPING; MOLECULAR TARGETED THERAPY; MUTATION; NEUROENDOCRINE TUMORS; PHENOTYPE; TERMINOLOGY AS TOPIC;

EID: 85017434208     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2017.33     Document Type: Review

References (106)

1. Vermeulen, L. & Snippert, H. J. Stem cell dynamics in homeostasis and cancer of the intestine. Nat. Rev. 14, 468-480 (2014).
2. Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913-2921 (2014).
3. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7-30 (2016).
4. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
5. Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47-52 (2016).
6. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202-209 (2014).
7. Mima, K. et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 1, 653-661 (2015).
8. Tahara, T. et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 74, 1311-1318 (2014).
9. Banales, J. M. et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat. Rev. Gastroenterol. Hepatol. 13, 261-280 (2016).
10. Zucman-Rossi, J., Villanueva, A., Nault, J. C. & Llovet, J. M. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149, 1226-1239.e4 (2015).
11. Fearon, E. R. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 6, 479-507 (2011).
12. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61, 759-767 (1990)
13. Wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (2007).
14. Punt, C. J., Koopman, M. & Vermeulen, L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat. Rev. Clin. Oncol. http://dx.doi.org/10.1038/nrclinonc.2016.171 (2016).
15. Peeters, M. et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin. Cancer Res. 21, 5469-5479 (2015).
16. Van Cutsem, E. et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J. Clin. Oncol. 33, 692-700 (2015).
17. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
18. Sargent, D. J. et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracilbased adjuvant therapy in colon cancer. J. Clin. Oncol. 28, 3219-3226 (2010).
19. Dotan, E. & Cohen, S. J. Challenges in the management of stage II colon cancer. Semin. Oncol. 38, 511-520 (2011).
20. DeVita, V. T. J., Lawrence, T. S. & Rosenberg, S. A. (eds) DeVita, Hellman, and Rosenbergs Cancer: Principles & Practice of Oncology 9th edn (Lippincott Williams and Wilkins, 2011).
21. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
22. Mlecnik, B. et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44, 698-711 (2016).
23. Galon, J. et al. The immune score as a new possible approach for the classification of cancer. J. Transl Med. 10, 1 (2012).
24. Jorissen, R. N. et al. Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer. Clin. Cancer Res. 15, 7642-7651 (2009).
25. You, Y. N., Rustin, R. B. & Sullivan, J. D. Oncotype DX colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: a review of the evidence. Surg. Oncol. 24, 61-66 (2015).
26. Tan, I. B. & Tan, P. Genetics: an 18-gene signature (ColoPrint) for colon cancer prognosis. Nat. Rev. Clin. Oncol. 8, 131-133 (2011).
27. Wang, X., Markowetz, F., De Sousa, E. M. F., Medema, J. P. & Vermeulen, L. Dissecting cancer heterogeneity-an unsupervised classification approach. Int. J. Biochem. Cell Biol. 45, 2574-2579 (2013).
28. Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350-1356 (2015).
29. Linnekamp, J. F., Wang, X., Medema, J. P. & Vermeulen, L. Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. Cancer Res. 75, 245-249 (2015).
30. Budinska, E. et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J. Pathol. 231, 63-76 (2013).
31. De Sousa, E. M. F. et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med. 19, 614-618 (2013).
32. Marisa, L. et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 10, e1001453 (2013).
33. Sadanandam, A. et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19, 619-625 (2013).
34. Schlicker, A. et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med. Genomics 5, 66 (2012).
35. Fessler, E. et al. TGFbeta signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Mol. Med. 8, 745-760 (2016).
36. Zhang, B. et al. Proteogenomic characterization of human colon and rectal cancer. Nature 513, 382-387 (2014).
37. Ghaneh, P., Costello, E. & Neoptolemos, J. P. Biology and management of pancreatic cancer. Gut 56, 1134-1152 (2007).
38. Hruban, R. H. & Fukushima, N. Pancreatic adenocarcinoma: update on the surgical pathology of carcinomas of ductal origin and PanINs. Mod. Pathol. 20 (Suppl. 1), S61-S70 (2007).
39. Roy, N. & Hebrok, M. Regulation of cellular identity in cancer. Dev. Cell 35, 674-684 (2015).
40. Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405 (2012).
41. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
42. Smit, V. T. et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 16, 7773-7782 (1988).
43. Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495-501 (2015).
44. Collins, M. A. et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Invest. 122, 639-653 (2012).
45. Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483 (2005).
46. Yachida, S. et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin. Cancer Res. 18, 6339-6347 (2012).
47. Donahue, T. R. et al. Integrative survival-based molecular profiling of human pancreatic cancer. Clin. Cancer Res. 18, 1352-1363 (2012).
48. Haider, S. et al. A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Genome Med. 6, 105 (2014).
49. Kirby, M. K. et al. RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. Mol. Oncol. 10, 1169-1182 (2016).
50. Stratford, J. K. et al. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med. 7, e1000307 (2010).
51. Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500-503 (2011).
52. Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor-and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168-1178 (2015).
53. Janky, R. et al. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. BMC Cancer 16, 632 (2016).
54. Kim, S. et al. Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer. Biomed. Eng. Online 13 (Suppl. 2), S5 (2014).
55. Namkung, J. et al. Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value. J. Gastroenterol. Hepatol. 31, 1160-1167 (2015).
56. Tang, S. et al. Stratification of digestive cancers with different pathological features and survival outcomes by microRNA expression. Sci. Rep. 6, 24466 (2016).
57. Humphrey, E. S. et al. Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling. Mol. Cell. Proteomics 15, 2671-2685 (2016).
58. Daemen, A. et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc. Natl Acad. Sci. USA 112, E4410-E4417 (2015).
59. Witkiewicz, A. K. et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744 (2015).
60. Herszenyi, L. & Tulassay, Z. Epidemiology of gastrointestinal and liver tumors. Eur. Rev. Med. Pharmacol. Sci. 14, 249-258 (2010).
61. Ohashi, S. et al. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology 149, 1700-1715 (2015).
62. Reid, B. J., Paulson, T. G. & Li, X. Genetic insights in Barretts esophagus and esophageal adenocarcinoma. Gastroenterology 149, 1142-1152.e3 (2015).
63. Gao, Y. B. et al. Genetic landscape of esophageal squamous cell carcinoma. Nat. Genet. 46, 1097-1102 (2014).
64. Lin, D. C. et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat. Genet. 46, 467-473 (2014).
65. Song, Y. et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509, 91-95 (2014).
66. Dulak, A. M. et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 45, 478-486 (2013).
67. Weaver, J. M. et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat. Genet. 46, 837-843 (2014).
68. Bass, A. J. et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet. 41, 1238-1242 (2009).
69. Su, H. et al. Global gene expression profiling and validation in esophageal squamous cell carcinoma and its association with clinical phenotypes. Clin. Cancer Res. 17, 2955-2966 (2011).
70. Sawada, G. et al. An integrative analysis to identify driver genes in esophageal squamous cell carcinoma. PLoS ONE 10, e0139808 (2015).
71. Bain, G. H. et al. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas. Br. J. Cancer 113, 1641 (2015).
72. Secrier, M. et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat. Genet. 48, 1131-1141 (2016).
73. The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169-175 (2017).
74. Higashi, H. et al. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc. Natl Acad. Sci. USA 99, 14428-14433 (2002).
75. Lauren, P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 64, 31-49 (1965).
76. Kakiuchi, M. et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat. Genet. 46, 583-587 (2014).
77. Wang, K. et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 43, 1219-1223 (2011).
78. Wang, K. et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat. Genet. 46, 573-582 (2014).
79. Zang, Z. J. et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 44, 570-574 (2012).
80. Deng, N. et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61, 673-684 (2012).
81. Pearson, A. et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov. 6, 838-851 (2016).
82. Bang, Y. J. et al. A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGR2) polysomy or gene amplification (amp): SHINE study [abstract]. J. Clin. Oncol 33 (Suppl.), a4014 (2015).
83. Boussioutas, A. et al. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res. 63, 2569-2577 (2003).
84. Tan, I. B. et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 141, 476-485.e11 (2011).
85. Lei, Z. et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology 145, 554-565 (2013).
86. US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT01100801 (2016).
87. Cristescu, R. et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21, 449-456 (2015).
88. Wu, Y. et al. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut 62, 1100-1111 (2013).
89. Lin, S. J. et al. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut 64, 1721-1731 (2015).
90. Oberg, K., Knigge, U., Kwekkeboom, D. & Perren, A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23 (Suppl. 7), vii124-vii130 (2012).
91. Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501-513 (2011).
92. Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514-523 (2011).
93. Hauck, L., Bitzer, M., Malek, N. & Plentz, R. R. Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors. Scand. J. Gastroenterol. 51, 55-59 (2016).
94. Ramage, J. K. et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61, 6-32 (2012).
95. Raymond, E., Garcia-Carbonero, R., Wiedenmann, B., Grande, E. & Pavel, M. Systemic therapeutic strategies for GEP-NETS: what can we expect in the future? Cancer Metastasis Rev. 33, 367-372 (2014).
96. Reid, M. D., Balci, S., Saka, B. & Adsay, N. V. Neuroendocrine tumors of the pancreas: current concepts and controversies. Endocr. Pathol. 25, 65-79 (2014).
97. Capdevila, J. et al. Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets. Cancer Metastasis Rev. 33, 345-351 (2014).
98. Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199-1203 (2011).
99. Francis, J. M. et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat. Genet. 45, 1483-1486 (2013).
100. Sadanandam, A. et al. A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics. Cancer Discov. 5, 1296-1313 (2015).
101. Cohen, R. L. & Settleman, J. From cancer genomics to precision oncology-tissues still an issue. Cell 157, 1509-1514 (2014).
102. Eason, K. & Sadanandam, A. Molecular or metabolic reprograming: what triggers tumor subtypes? Cancer Res. 76, 5195-5200 (2016).
103. Roepman, P. et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int. J. Cancer 134, 552-562 (2014).
104. Trinh, A. et al. Practical and robust identification of molecular subtypes in colorectal cancer by immunohistochemistry. Clin. Cancer Res. 23, 387-398 (2017).
105. Noll, E. M. et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat. Med. 22, 278-287 (2016).
106. Best, M. G. et al. RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 28, 666-676 (2015).